Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia

Nathan A Stephens; Iain J Gallagher; Olav Rooyackers; Richard J Skipworth; Ben H Tan; Troels Marstrand; James A Ross; Denis C Guttridge; Lars Lundell; Kenneth C Fearon; James A Timmons

doi:10.1186/gm122

Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia

Nathan A Stephens, Iain J Gallagher, Olav Rooyackers, Richard J Skipworth, Ben H Tan, Troels Marstrand, James A Ross, Denis C Guttridge, Lars Lundell, Kenneth C Fearon, James A Timmons

Research output: Contribution to journal › Article › peer-review

Abstract

Cancer cachexia is a multi-organ tissue wasting syndrome that contributes to morbidity and mortality in many cancer patients. Skeletal muscle loss represents an established key feature yet there is no molecular understanding of the disease process. In fact, the postulated molecular regulators of cancer cachexia originate largely from pre-clinical models and it is unclear how these translate to the clinical environment.

Original language	English
Pages (from-to)	1
Journal	Genome Medicine
Volume	2
Issue number	1
DOIs	https://doi.org/10.1186/gm122
Publication status	Published - 2010

Access to Document

10.1186/gm122

Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia
© 2010 Stephens et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Final published version, 763 KB

http://genomemedicine.com/content/2/1/1

Cite this

@article{89e98b86668d45ee8ce2ee0487d9b152,

title = "Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia",

abstract = "Cancer cachexia is a multi-organ tissue wasting syndrome that contributes to morbidity and mortality in many cancer patients. Skeletal muscle loss represents an established key feature yet there is no molecular understanding of the disease process. In fact, the postulated molecular regulators of cancer cachexia originate largely from pre-clinical models and it is unclear how these translate to the clinical environment.",

author = "Stephens, \{Nathan A\} and Gallagher, \{Iain J\} and Olav Rooyackers and Skipworth, \{Richard J\} and Tan, \{Ben H\} and Troels Marstrand and Ross, \{James A\} and Guttridge, \{Denis C\} and Lars Lundell and Fearon, \{Kenneth C\} and Timmons, \{James A\}",

year = "2010",

doi = "10.1186/gm122",

language = "English",

volume = "2",

pages = "1",

journal = "Genome Medicine",

issn = "1756-994X",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia

AU - Stephens, Nathan A

AU - Gallagher, Iain J

AU - Rooyackers, Olav

AU - Skipworth, Richard J

AU - Tan, Ben H

AU - Marstrand, Troels

AU - Ross, James A

AU - Guttridge, Denis C

AU - Lundell, Lars

AU - Fearon, Kenneth C

AU - Timmons, James A

PY - 2010

Y1 - 2010

N2 - Cancer cachexia is a multi-organ tissue wasting syndrome that contributes to morbidity and mortality in many cancer patients. Skeletal muscle loss represents an established key feature yet there is no molecular understanding of the disease process. In fact, the postulated molecular regulators of cancer cachexia originate largely from pre-clinical models and it is unclear how these translate to the clinical environment.

AB - Cancer cachexia is a multi-organ tissue wasting syndrome that contributes to morbidity and mortality in many cancer patients. Skeletal muscle loss represents an established key feature yet there is no molecular understanding of the disease process. In fact, the postulated molecular regulators of cancer cachexia originate largely from pre-clinical models and it is unclear how these translate to the clinical environment.

UR - https://www.scopus.com/pages/publications/78449253911

U2 - 10.1186/gm122

DO - 10.1186/gm122

M3 - Article

C2 - 20193046

SN - 1756-994X

VL - 2

SP - 1

JO - Genome Medicine

JF - Genome Medicine

IS - 1

ER -

Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia

Abstract

Access to Document

Other files and links

Fingerprint

Cite this